Key Factors and Improving Paths of Promoting Long-Acting Injections in Communities in Beijing

Yu XIN; Chen CHEN; Yao DONG; Jinqi ZHU; Yun CHEN; Qingzhi HUANG; Junli ZHU

doi:10.3881/j.issn.1000-503X.16254

PDF(888 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (3) : 414-424. DOI: 10.3881/j.issn.1000-503X.16254

Original Articles

Key Factors and Improving Paths of Promoting Long-Acting Injections in Communities in Beijing

Yu XIN ¹ ,
Chen CHEN ¹ ,
Yao DONG ¹ ,
Jinqi ZHU ¹ ,
Yun CHEN ² ,
Qingzhi HUANG ² ,
Junli ZHU ¹

Author information +

History +

Abstract

Objective To investigate the key factors influencing the implementation of long-acting injection-promoting policies and propose effective improving paths.Methods Qualitative interviews were carried out for stakeholders involved in the promotion of long-acting injections,based on the consolidated framework for implementation research.Additionally,countermeasures for identified barriers were proposed based on expert recommendations for implementation changes.Results A total of 46 health administrators,healthcare workers,and patients in Beijing were interviewed.The study identified several barriers in the strength and quality of evidence,adaptability,relative advantage,complexity and cost,patient needs and resources,external collaboration,external policies and incentives,organizational structural characteristics,and self-efficacy.Conclusions From the perspectives and experiences of stakeholders,the promotion of long-acting injections has shown initial success but still faces multiple obstacles.It is recommended that efforts should be made to coordinate and adapt policies,improve and incentivize relative organizations,and continuously strengthen the advocacy and education for individuals.

Key words

qualitative research / consolidated framework for implementation research / community mental health / psychotropic drugs / health service survey

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Yu XIN , Chen CHEN , Yao DONG , et al . Key Factors and Improving Paths of Promoting Long-Acting Injections in Communities in Beijing[J]. Acta Academiae Medicinae Sinicae. 2025, 47(3): 414-424 https://doi.org/10.3881/j.issn.1000-503X.16254

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Olayinka O, Oyelakin A, Cherukupally K, et al. Use of long-acting injectable antipsychotic in an inpatient unit of a community teaching hospital[J]. Psychiatry J, 2019,2019:8629030.DOI:10.1155/2019/8629030. Cited in this article [1]

[2]	Bjedov S, Ciglar M, Maleković H. Attitudes of Croatian patients with severe mental illness towards long-acting injectable antipsychotics[J]. Psychiatr Danub, 2016,28(3):278-283. Cited in this article [1]

[3]	Barkhof E, Meijer CJ, de Sonneville LM, et al. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade[J]. Eur Psychiatry, 2012, 27(1):9-18.DOI:10.1016/j.eurpsy.2011.02.005. Cited in this article [1]

[4]

Peuskens

, Olivares

, Pecenak

, et al. Treatment retention with risperidone long-acting injection:24-month results from the electronic schizophrenia treatment adherence registry(e-STAR)in six countries[J]. Curr Med Res Opin, 2010, 26(3):501-509.DOI:10.1185/03007990903488670.

Cited in this article [1]

[5]	Peuskens J, Mertens C, Kusters J, et al. Longacting risperidone in the treatment of schizophrenia:data from a 24-month Belgian electronic schizophrenia adherence registry(eSTAR):an observational study[J]. Acta Psychiatr Belg, 2010, 110:34-46.DOI:10.1111/eip.12017. Cited in this article [1]

[6]	Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis:post hoc comparison of two studies[J]. Clin Ther, 2008, 30(12):2378-2386.DOI:10.1016/j.clinthera.2008.12.020. Cited in this article [1]

[7]	Tang CT, Chua EC, Chew QH, et al. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region[J]. Asia Pac Psychiatry, 2020, 12(4):e12393.DOI:10.1111/appy.12393. Cited in this article [1]

[8]	Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice:a consolidated framework for advancing implementation science[J]. Implement Sci, 2009,4:50.DOI:10.1186/1748-5908-4-50. Cited in this article [2]

[9]	Waltz TJ, Powell BJ, Fernández ME, et al. Choosing implementation strategies to address contextual barriers:diversity in recommendations and future directions[J]. Implement Sci, 2019,14:42.DOI:10.1186/s13012-019-0892-4. Cited in this article [2]

[10]	Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies:results from the expert recommendations for implementing change(ERIC)project[J]. Implement Sci, 2015,10:21.DOI:10.1186/s13012-015-0209-1. Cited in this article [1]

[11]	Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the consolidated framework for implementation research(CFIR)[J]. Implement Sci,8:51.DOI:10.1186/1748-5908-8-51. Cited in this article [1]

[12]	Robinson DG, Subramaniam A, Fearis PJ, et al. Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics[J]. Psychiatr Serv, 2020, 71(4):337-342.DOI:10.1176/appi.ps.201900236. Cited in this article [1]

[13]	Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia[J]. CNS drugs, 2016,30:689-701.DOI:10.1007/s40263-016-0350-7. Cited in this article [2]

[14]	Kirschner M, Theodoridou A, Fusar-Poli P, et al. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis[J]. Ther Adv Psychopharmacol, 2013, 3(2):89-99.DOI:10.1177/2045125312464106. Cited in this article [2]

[15]	Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics:part I—patient perspectives[J]. Can J Psychiatry, 2013, 58(5_suppl):14-22.DOI:10.1177/088740341305805s03. Cited in this article [3]

[16]

Weiden

, Roma

, Velligan

, et al. The challenge of offering long-acting antipsychotic therapies:a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia[J]. J Clin Psychiatry, 2015, 76(6):2470.DOI:10.4088/JCP.13m08946.

Cited in this article [1]

[17]	Velligan DI, Medellin E, Draper M, et al. Barriers to,and strategies for,starting a long acting injection clinic in a community mental health center[J]. Community Ment Health J, 2011,47:654-659.DOI:10.1007/s10597-011-9389-6. Cited in this article [2]

[18]	Heres S, Reichhart T, Hamann J, et al. Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia[J]. Eur Psychiatry, 2011, 26(5):297-301.DOI:10.1016/j.eurpsy.2009.12.020. Cited in this article [1]

[19]	Citrome L, Belcher E, Stacy S, et al. Management of schizophrenia with long-acting injectable antipsychotic medications:an assessment of the educational needs of clinicians[J]. Neuropsychiatr Dis Treat, 2022,18:111.DOI:10.2147/NDT.S326299. Cited in this article [2]

[20]	Paton C, Okocha CI, Patel MX. Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised[J]. Ther Adv Psychopharmacol, 2022,12:20451253211072347.DOI:10.1177/20451253211072347. Cited in this article [1]

[21]	李畅, 黄慧腾, 王怡君, 等. 基于长效针剂的医院社区一体化精神分裂症管理模式现状调研[J]. 临床精神医学杂志, 2022, 32(6):445-448.DOI:10.3969/j.issn.1005-3220.2022.06.008. Cited in this article [1]

[22]	Zhu J, Chen Y, Lu W, et al. Attitudes and willingness to accept long-acting injections for patients with schizophrenia in Beijing:a cross-sectional investigation based on samples from the communities[J]. Front Public Health, 2021,9:770276.DOI:10.3389/fpubh.2021.770276. Cited in this article [1]

[23]	Liu Q, Zheng Z, Zheng J, et al. Health communication through news media during the early stage of the COVID-19 outbreak in China:digital topic modeling approach[J]. J Med Internet Res, 2020, 22(4):e19118.DOI:10.2196/19118. Cited in this article [1]

[24]	李佳博, 欧阳江峰, 杨丁, 等. 长效针剂在三省部分社区精神分裂症患者中的应用现状及存在问题[J]. 山东大学学报(医学版), 2022, 60(6):107-113,121.DOI:10.6040/j.issn.1671-7554.0.2021.1237. Cited in this article [1]

[25]	Dalton A, Lambert T, Schrover R, et al. The cost associated with administering risperidone long-acting injections in the Australian community[J]. BMC Health Serv Res, 2011, 11(1):236.DOI:10.1186/1472-6963-11-236. Cited in this article [1]

[26]

Blixen

, Lema

, Mbwambo

, et al. Community perceptions of barriers to management of chronic psychotic disorders and knowledge and attitudes about long-acting injectable antipsychotic medication:qualitative study in Dar es Salaam,Tanzania[J]. BJPsych Open, 2020, 6(2):e27.DOI:10.1192/bjo.2020.4.

Cited in this article [1]

[27]	Kane JM. Organizational barriers to using long-acting injectable antipsychotics in practice[J]. J Clin Psychiatry, 2014, 75(6):e16.DOI:10.4088/JCP.13024tx1c. Cited in this article [1]

[28]

Munday

, Greene

, Chang

, et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia:real-world evidence from US claims data[J]. Curr Med Res Opin, 2019, 35(7):1231-1239.DOI:10.1080/03007995.2019.1571295.

Cited in this article [1]

[29]	Shah A, Xie L, Kariburyo F, et al. Treatment patterns,healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics[J]. Adv Ther, 2018, 35:1994-2014.DOI:10.1007/s12325-018-0786-x. Cited in this article [1]

[30]	Grover S, Sahoo S, Subodh B, et al. Attitude and perceptions of patients towards long acting depot injections(LAIs)[J]. Asian J Psychiatry, 2019, 44:200-208.DOI:10.1016/j.ajp.2019.07.052. Cited in this article [1]

[31]	Sugawara N, Kudo S, Ishioka M, et al. Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan[J]. Neuropsychiatr Dis Treat, 2019, 15:205-211.DOI:10.2147/NDT.S188337.